Adicet Bio Statistics
Total Valuation
Adicet Bio has a market cap or net worth of $97.52 million. The enterprise value is -$7.81 million.
| Market Cap | 97.52M |
| Enterprise Value | -7.81M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Adicet Bio has 10.76 million shares outstanding. The number of shares has increased by 65.16% in one year.
| Current Share Class | 9.36M |
| Shares Outstanding | 10.76M |
| Shares Change (YoY) | +65.16% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 37.85% |
| Float | 7.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.71, with a Debt / Equity ratio of 0.11.
| Current Ratio | 6.71 |
| Quick Ratio | 6.59 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,280.35 |
Financial Efficiency
Return on equity (ROE) is -78.08% and return on invested capital (ROIC) is -46.02%.
| Return on Equity (ROE) | -78.08% |
| Return on Assets (ROA) | -41.66% |
| Return on Invested Capital (ROIC) | -46.02% |
| Return on Capital Employed (ROCE) | -79.67% |
| Weighted Average Cost of Capital (WACC) | 11.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$970,333 |
| Employee Count | 102 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Adicet Bio has paid $143,000 in taxes.
| Income Tax | 143,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.06% in the last 52 weeks. The beta is 1.59, so Adicet Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | -25.06% |
| 50-Day Moving Average | 8.60 |
| 200-Day Moving Average | 8.10 |
| Relative Strength Index (RSI) | 55.81 |
| Average Volume (20 Days) | 91,554 |
Short Selling Information
The latest short interest is 262,357, so 2.44% of the outstanding shares have been sold short.
| Short Interest | 262,357 |
| Short Previous Month | 397,053 |
| Short % of Shares Out | 2.44% |
| Short % of Float | 3.53% |
| Short Ratio (days to cover) | 2.96 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -103.71M |
| Pretax Income | -98.83M |
| Net Income | -98.97M |
| EBITDA | -98.12M |
| EBIT | -103.71M |
| Earnings Per Share (EPS) | -$10.52 |
Balance Sheet
The company has $118.19 million in cash and $12.85 million in debt, with a net cash position of $105.34 million or $9.79 per share.
| Cash & Cash Equivalents | 118.19M |
| Total Debt | 12.85M |
| Net Cash | 105.34M |
| Net Cash Per Share | $9.79 |
| Equity (Book Value) | 120.14M |
| Book Value Per Share | 11.16 |
| Working Capital | 102.76M |
Cash Flow
In the last 12 months, operating cash flow was -$84.53 million and capital expenditures -$438,000, giving a free cash flow of -$84.97 million.
| Operating Cash Flow | -84.53M |
| Capital Expenditures | -438,000 |
| Depreciation & Amortization | 5.59M |
| Net Borrowing | -150,000 |
| Free Cash Flow | -84.97M |
| FCF Per Share | -$7.89 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Adicet Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -65.16% |
| Shareholder Yield | n/a |
| Earnings Yield | -101.49% |
| FCF Yield | -87.12% |
Analyst Forecast
The average price target for Adicet Bio is $33.17, which is 266.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $33.17 |
| Price Target Difference | 266.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 30, 2025. It was a reverse split with a ratio of 1:16.
| Last Split Date | Dec 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |